Skip to main content
Clinical Trials/JPRN-UMIN000026927
JPRN-UMIN000026927
Completed
未知

A multicenter, prospective observational study of pegfilgrastim for the management of febrile neutropenia during ramucirumab plus docetaxel for patients with advanced non-small cell lung cancer (CJLSG 1602) - Observational study of pegfilgrastim for the management of febrile neutropenia during ramucirumab plus docetaxel

Central Japan Lung Study Group (CJLSG)0 sites35 target enrollmentApril 10, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Central Japan Lung Study Group (CJLSG)
Enrollment
35
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 10, 2017
End Date
November 6, 2018
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Central Japan Lung Study Group (CJLSG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Active infection 2\) Patients had brain tumors and/or brain metastases (symptomatic or requiring treatment) 3\) Evidence of tumor invading a perihilar blood vessel 4\) Having a cavitating lung tumor 5\) History of pulmonary hemorrhage or hemoptysis over 2\.5 ml within 2 months 6\) Evidence of tumor invading segmental bronchus 7\) Severe gastrointestinal complications 8\) Having a history or evidence of thrombosis 9\) Severe hypertension 10\) Having a history or evidence of ILD complication 11\) Having an allergy of ramucirumab, docetaxel and pegfilgrastim 12\) Having a severe mental disorder 13\) Pregnant woman 14\) Patients whose participation in the trial is judged to be inappropriate by the doctor

Outcomes

Primary Outcomes

Not specified

Similar Trials